The Management of Hypertension

Abrams W. B. Pocelinko R. Klausner M. Hanauer L. Whitman E. N. (1964). Clinical pharmacological studies with debrisoquin sulphate, a new antihypertensive agent. J. New Drugs, 4, 268.

Ballantyne A. J. Michaelson I. C. (1962). Textbook of the fundus of the eye. Edinburgh: E. and S. Livingstone Ltd.

Brackenridge R. D. C. (1962). The medical aspects of life assurance. London: Staples Press (quoting from ‘Build and Blood Pressure Study’, 1959, Society of Actuaries).

Cahal D. A. (1966). Methyl dopa and haemolytic anaemia. (Committee on Safety of Drugs.) Correspondence, Lancet, 1, 201.

Carstairs K. Worlledge S. Dollery C. T. Breckenridge A. (1966). Correspondence, Lancet, 1, 201.

Cotton S. G. Montuschi E. (1966). Side effects of guanoxan. Correspondence, Brit. med. J., 1, 51.

Darnborough J. (1966). Correspondence, Lancet, 1, 262.

Dewar H. A. Peaston M. J. T. (1964). Three cases resembling polyarteritis nodosa arising during treatment with guanethidine. Brit. med. J., 2, 609.

Goldring W. Chasis H. (1965). Antihypertensive drug therapy. An appraisal. Arch, intern. Med., 115, 523.

Hafkenschiel J. H. Schmitthenner J. E. Daugherty E. A. (1965). Primary hypertension. Survey of the survival of patients with established diastolic hypertension after ten years of medical and surgical treatment. Amer. J. Cardiol., 16, 61.

Hamilton M. Thompson E. N. Wisniewski , (1964). The role of blood pressure control in preventing complications of hypertension. Lancet, 1, 235.

Harington M. Kincaid-Smith P. McMichael J. (1959). Results of treatment in malignant hypertension. A seven year experience in 94 cases. Brit. med. J., 2, 969.

Hayes D. (1966). Correspondence, Lancet, 1, 365.

Johnson P. Kjtchin A. H. Lowther C. P. Turner R. W. D. (1966). Treatment of hypertension with methyl dopa. Brit. med. J., 1, 133.

Kincaid-Smith P. McMichael J. Murphy E. A. (1958). The clinical course and pathology of hypertension with papilloedema (malignant hypertension). Quart. J. med., 27, 117.

Leishman A. W. D. (1959). Hypertension treated and untreated. A study of 400 cases. Brit. med. J., 1, 1361.

Lewis J. A. Kim O. S. Nicholls D. M. (1965). Effects of treatment upon kidney function in hypertension. Amer. J. med. Sci., 39, 177.

Luke R. G. Kennedy A. C. (1964). Methyl dopa in treatment of hypertension due to chronic renal disease. Brit. med. J., 1, 27.

Moe R. A. Bates H. M. Palkoski Z. M. Banziger R. (1964). Cardiovascular effects of 3–4-dihydro-2(1H) isoquinoline carboxamidine (Declinax). Current therapeutic research, 6, 299.

McMichael J. Murphy E. A. (1955). Methonium treatment of severe and malignant hypertension. J. Chron. Dis., 1, 527.

Pears M. A. Pickering G. W. (1965). Antihypertensive drug therapy. Another appraisal. Arch. intern. med., 115, 526.

Scheie H. G. (1953). Evaluation of the ophthalmoscopic changes of hypertension and arteriolar sclerosis. Amer. Arch. Ophthalmol., 49, 117.

Scottish Medical Journal (1964). New drugs for hypertension. Scot. med. J., 9, 176.

Shelburner S. A. (1965). Hypertensive retinal disease, p. 9. New York and London: Grune and Stratton.

Simpson F. O. Gilchrist A. R. (1958). Prognosis in untreated hypertensive vascular disease. Scot. med. J., 3, 1.

Sjoerdsma A. Engelman K. Specter S. Udenfriend S. (1965). Inhibition of catecholamine synthesis in man with alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Lancet, 2, 1092.

Smirk H. Hodge J. V. (1963). Causes of death in treated hypertensive patients. Based on 82 deaths during 1959–61 among an average hypertensive population at risk of 518 persons. Brit. med. J., 2, 1221.

Smithwick R. H. (1955). Hypertensive vascular disease. Results and indications for splanchnicectomy. J. Chron. Dis., 1, 477.

Sokolow M. Perloff D. (1965). The choice of drugs and the management of essential hypertension. Prog. Cardiovasc. Dis., 8, 253.

Wagener H. P. Keith N. M. (1939). Diffuse arteriolar disease with hypertension and the associated retinal lesions. Medicine, 18, 317.